SEC Tracker
Get the app
LXEO · XBRL financial data

Lexeo Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (LXEO's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Research and development17,2468,210*15,74216,56023,42318,366*17,17114,72115,69516,210*15,70319,027
General and administrative3,0276,764*7,5496,9908,1209,016*16,63415,9675,9536,906*6,6308,993
Total operating expenses20,27314,974*23,29123,55031,54327,382*33,80530,68821,64823,116*22,33328,020
Operating income (loss)(20,273)(14,974)*(23,291)(23,550)(31,543)(27,382)*(33,805)(30,688)(21,648)(23,116)*(22,333)(28,020)
Interest income4881,102*1,6512,3482,0921,465*1,1931,2681,4562,213*2,1132,194
Interest expense5250*37353530*28252220*1714
Other income (expense)1(7)*(5)(1)(3)0*(4)(14)(9)9*(1)(6)
Income tax expense (benefit)—————year only———year only——
Net income (loss)(20,108)(14,187)*(21,682)(21,238)(29,489)(25,924)*(32,656)(26,103)(20,283)(20,919)*(20,196)(25,867)
Earnings per share, basic USD per share(12.36)—(0.77)(0.64)(0.89)(0.78)*(0.99)(0.60)(0.33)—(0.25)(0.30)
Earnings per share, diluted USD per share(12.36)—(0.77)(0.64)(0.89)(0.78)*(0.99)(0.60)(0.33)—(0.25)(0.30)
Weighted average shares, basic thousands of shares1,627—27,98033,00233,06333,077*33,11443,57460,981—81,18485,627
Weighted average shares, diluted thousands of shares1,627—27,98033,00233,06333,077*33,11443,57460,981—81,18485,627

Balance sheet

CSV

Fiscal quarters (LXEO's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents35,449121,466195,060174,981157,02035,01428,91335,48040,99663,00071,76892,834
Short-term investments—————86,50470,918—————
Marketable securities—————86,504—97,41381,768118,767121,275118,869
Marketable securities, non-current—————7,012—19,613064,80134,51022,468
Prepaid and other current assets—2,8283,0292,1682,4384,6035,4437,1695,0296,6257,8196,205
Total current assets38,874124,294198,089177,149159,458126,121105,274140,062127,793188,392200,862217,908
Property and equipment, net9801,0561,0441,2051,1801,0281,0451,1151,2301,1391,1011,121
Right-of-use asset9,7769,4429,1208,7818,4358,0697,7087,3406,9636,5786,1855,783
Total assets54,724139,807213,205192,007173,865146,942125,690176,068143,844268,688250,356254,898
Accounts payable2,6553,7944,2975,7658,4386,41711,98120,0254,6564,8563,3354,179
Total current liabilities23,03517,23921,63018,87726,81822,84630,82331,59317,27116,80814,18915,692
Lease liability, non-current8,1137,7867,4717,1396,7916,4376,0545,6805,2884,8844,4724,050
Total liabilities32,49926,27230,25527,05934,53930,10037,57537,85023,01322,01918,85919,837
Accumulated deficit(167,653)(181,840)(203,522)(224,760)(254,249)(280,173)(312,829)(338,932)(359,215)(380,134)(400,330)(426,197)
Total stockholders' equity(162,808)113,535182,950164,948139,326116,84288,115138,218120,831246,669231,497235,061
Total liabilities and equity54,724139,807213,205192,007173,865146,942125,690176,068143,844268,688250,356254,898
Common shares outstanding (cover page) thousands of shares26,64626,66932,94533,06133,06633,19733,19754,00172,98774,08778,52282,046

Cash flows

CSV

Fiscal quarters (LXEO's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(20,108)(14,187)*(21,682)(21,238)(29,489)(25,924)*(32,656)(26,103)(20,283)(20,919)*(20,196)(25,867)
Stock-based compensation875804*2,3312,846*3,790*3,507*3,6973,071*2,651*2,713*2,7555,690*
Net cash from operating activities(13,949)*(13,981)*(14,867)(20,152)*(17,806)*(28,326)*(21,716)(27,219)*(29,547)*(20,079)*(21,144)(17,597)*
Purchases of property and equipment3*73*185213*83*0*——289*0*357*
Net cash from investing activities(53)*(73)*(193)(218)*(83)*(93,583)*15,600(39,174)*35,011*(101,689)*27,46014,264*
Proceeds from issuing common stock——————1700*101*(1)*14324,857*
Net cash from financing activities3,912*100,071*88,654291*(72)*(97)*1172,960*52*143,772*2,45224,399*
Net change in cash(10,090)*86,017*73,594(20,079)*(17,961)*(122,006)*(6,105)6,567*5,516*22,004*8,76821,066*

Compare with peers

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Lexeo Therapeutics92,834not reported(17,597)*82.0M13.3 quarters 10-QJun 30, 2026
SELLAS Life Sciences Group138,343not reported(7,588)*201.9M18.2 quarters 10-QJun 30, 2026
Precigen14,95974,14811,883*358.5M— 10-QSep 30, 2026
Perspective Therapeutics48,488not reported(20,650)*114.2M11.5 quarters 10-QJun 30, 2026
Rocket Pharmaceuticals224,5070(39,613)*109.8M7.2 quarters 10-QJun 30, 2026
Natures Sunshine Products89,377116,60310,750*17.3M— 10-QSep 30, 2026
Lifecore Biomedical23,03525,3226,946*37.9M— 10-QSep 30, 2026
Tvardi Therapeutics15,765not reported(9,228)*13.3M1.7 quarters 10-QJun 30, 2026
Silence Therapeutics72,05401,518*141.7M— 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched . The filing on SEC.gov is the record.